Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia

This study has been completed.

Study NCT00366418 Information provided by National Institutes of Health Clinical Center (CC)

First Received: August 17, 2006 Last Updated: February 25, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	June 2009
Primary Completion Date:	June 2009 (Final data collection date for primary outcome measure)

No publications provided by National Institutes of Health Clinical Center (CC)

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Aue G, Lindorfer MA, Beum PV, Pawluczkowycz AW, Vire B, Hughes T, Taylor RP, Wiestner A. Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia. Haematologica. 2010 Feb;95(2):329-32. Epub 2009 Aug 13.